Welwyn Garden City, UK, 21st April 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with a third (undisclosed) pharmaceutical company. The research, which will take advantage of CN Bio’s full viral lifecycle model of Hepatitis B, Quantum-B®, will be performed by CN Bio in the company’s newly opened Containment Level 3 laboratory in Welwyn Garden City, UK.
- CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit 26th April 2022
- The lung in crisis: fighting back against pathogens, infections and inflammation with predictive in vitro respiratory models that accelerate drug discovery 23rd March 2022
- Debunking the 9 Myths of Organ-on-a-Chip Technology 24th February 2022